Write your message
Volume 7, Issue 3 (May & June 2022)                   J Obstet Gynecol Cancer Res 2022, 7(3): 3-3 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mousavi A, Akhavan S, Sabzi shahrbabaki F, Izadi-mood N, Yarandi F, Ghazimoghadam M, et al . Assessment of the diagnostic value of High-risk HPV molecular-based methods for triage of Iranian women with abnormal cytological findings of ASC-US and LSIL. J Obstet Gynecol Cancer Res. 2022; 7 (3) :3-3
URL: http://jogcr.com/article-1-437-en.html
1- Department of Gynecology-Oncology, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran , Azamsadat_mousavi@yahoo.com
2- Department of Gynecology-Oncology, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
3- Department of Gynecology and Obstetrics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4- Department of Pathology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5- Department of Gynecology-Oncology, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran
6- Department of Pathology, Armin Pathobiology and Genetics Laboratory, Tehran, Iran
7- Department of Molecular Diagnosis, Armin Pathobiology and Genetics Laboratory, Tehran, Iran
8- Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran
Abstract:   (91 Views)
Background & Objective: Recent advances in molecular testing of Human Papillomavirus (HPV) increased the accuracy of cervical screening programs. This study intended to estimate the diagnostic value of High-Risk (HR) HPV DNA- and E6/E7 mRNA-based methods for triage of Iranian women with abnormal cytological results regarding the histopathological cut-off.
Methods: In this cross-sectional study, 360 non-pregnant women (≥ 21 years) who faced abnormal cytological findings of ASC-US and LSIL were enrolled and referred for further diagnostic protocols. The INNO-LiPA® HPV Genotyping Extra-II and Aptima HPV assay kit were used as DNA- and E6/E7 mRNA-based methods for detection of HR-HPV. Regarding the CIN-2+ histopathological cut-off, the diagnostic value of each molecular-based assay was calculated.
Results: Among the study participants, 260 cases had ASC-US, and 100 had LSIL cytological results. The overall positivity rate for DNA- and mRNA-based methods was 74.4% (268/360) and 64.2% (231/360), respectively. Fifty-nine (16.4%) individuals showed CIN-2+ histopathological result. The DNA-based test showed higher sensitivity (100%) than the mRNA-based method (93.2%), while the mRNA-based method revealed greater clinical specificity of 41.5% compared to the DNA-based test of 30.6%.
Conclusion: Our data revealed appropriate clinical sensitivity of the molecular-based methods for triage of Iranian women with abnormal cytological results; however, the mRNA-based method showed greater specificity for detection of CIN-2+.
     
Systematic Review: Original Research | Subject: Gynecology Oncology
Received: 2021/06/29 | Accepted: 2021/08/13 | Published: 2021/11/25

References
1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-53. [DOI:10.1002/ijc.31937] [PMID]
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F [DOI:10.1002/(SICI)1096-9896(199909)189:13.0.CO;2-F]
3. Humans IWGotEoCRt. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441.
4. Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology. 2013;445(1-2):224-31. [DOI:10.1016/j.virol.2013.07.015] [PMID]
5. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012;30 Suppl 5:F24-33. [DOI:10.1016/j.vaccine.2012.05.089] [PMID] [PMCID]
6. Correa Mda S, Silveira DS, Siqueira FV, Facchini LA, Piccini RX, Thume E, et al. [Pap test coverage and adequacy in the South and Northeast of Brazil]. Cad Saude Publica. 2012;28(12):2257-66. [DOI:10.1590/S0102-311X2012001400005] [PMID]
7. Chen YC, Liu HY, Li CY, Lee NY, Ko WC, Chou CY, et al. Low Papanicolaou smear screening rate of women with HIV infection: a nationwide population-based study in Taiwan, 2000-2010. J Womens Health (Larchmt). 2013;22(12):1016-22. [DOI:10.1089/jwh.2012.4127] [PMID] [PMCID]
8. Bobdey S, Sathwara J, Jain A, Balasubramaniam G. Burden of cervical cancer and role of screening in India. Indian J Med Paediatr Oncol. 2016;37(4):278-85. [DOI:10.4103/0971-5851.195751] [PMID] [PMCID]
9. Geldenhuys L, Murray ML. Sensitivity and specificity of the Pap smear for glandular lesions of the cervix and endometrium. Acta Cytol. 2007;51(1):47-50. [DOI:10.1159/000325682] [PMID]
10. Boulet GA, Horvath CA, Berghmans S, Bogers J. Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiol Biomarkers Prev. 2008;17(4):810-7. [DOI:10.1158/1055-9965.EPI-07-2865] [PMID]
11. Stoler MH, Wright TC, Jr., Cuzick J, Dockter J, Reid JL, Getman D, et al. APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am J Obstet Gynecol. 2013;208(2):144 e1-8. [DOI:10.1016/j.ajog.2012.12.003] [PMID]
12. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S1-S27. [DOI:10.1097/LGT.0b013e318287d329] [PMID]
13. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095-101. [DOI:10.1002/ijc.21955] [PMID]
14. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-88. [DOI:10.1056/NEJMoa071430] [PMID]
15. Baseman JG, Kulasingam SL, Harris TG, Hughes JP, Kiviat NB, Mao C, et al. Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. Am J Obstet Gynecol. 2008;199(1):26 e1-8. [DOI:10.1016/j.ajog.2007.11.051] [PMID]
16. Moscicki AB, Ma Y, Jonte J, Miller-Benningfield S, Hanson E, Jay J, et al. The role of sexual behavior and human papillomavirus persistence in predicting repeated infections with new human papillomavirus types. Cancer Epidemiol Biomarkers Prev. 2010;19(8):2055-65. [DOI:10.1158/1055-9965.EPI-10-0394] [PMID] [PMCID]
17. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res. 2008;68(21):8813-24. [DOI:10.1158/0008-5472.CAN-08-1380] [PMID] [PMCID]
18. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2536-45. [DOI:10.1158/1055-9965.EPI-08-0306] [PMID] [PMCID]
19. Lie AK, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, et al. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol. 2005;97(3):908-15. [DOI:10.1016/j.ygyno.2005.02.026] [PMID]
20. Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES, Skjeldestad FE. HPV mRNA is more specific than HPV DNA in triage of women with minor cervical lesions. PLoS One. 2014;9(11):e112934. [DOI:10.1371/journal.pone.0112934] [PMID] [PMCID]
21. Austin RM. (2018) Technology matters: The clinical utility of HPV mRNA testing compared to DNA testing. Promotional supplement to Contemporary OB/GYN.
22. Kurman RJ CM, Herrington CS. World Health Organisation Classification of Tumours of the Female Reproductive Organs. 4th Revised ed. International Agency for Research on Cancer, 2014.
23. Mousavi AS, Pouryasin A, Yarandi F, Pirzadeh L, Alipour A, Khodadad S, et al. Assessment of Cervical Cancer Molecular-Based Screening Tools; HPV-DNA Detection versus E6/E7 mRNA Testing; First Report of a Prospective Cohort Study among Iranian Women. Iran J Public Health. 2020;49(9):1734-42. [DOI:10.18502/ijph.v49i9.4093]
24. Szklo M NF, Reilly T, Parker K (2014). Epidemiology : beyond the basics. 4th Edition. ISBN-10: 128411659X.
25. Jamdar F, Farzaneh F, Navidpour F, Younesi S, Balvayeh P, Hosseini M, et al. Prevalence of human papillomavirus infection among Iranian women using COBAS HPV DNA testing. Infect Agent Cancer. 2018;13:6. [DOI:10.1186/s13027-018-0178-5] [PMID] [PMCID]
26. Tewari P, White C, Kelly L, Pilkington L, Keegan H, D'Arcy T, et al. Clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay in the management of women referred to colposcopy with minor cytological abnormalities. Diagn Cytopathol. 2018;46(12):987-92. [DOI:10.1002/dc.24066] [PMID]
27. Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, Ho L, et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol. 2012;50(6):1867-73. [DOI:10.1128/JCM.00181-12] [PMID] [PMCID]
28. cobas® 4800 HPV Test [package insert]. Branchburg NRMS, Inc; 2018.
29. Castle PE, Reid J, Dockter J, Getman D. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology. J Clin Virol. 2015;69:52-5. [DOI:10.1016/j.jcv.2015.05.006] [PMID]
30. Moss SM, Bailey A, Cubie H, Denton K, Sargent A, Muir P, et al. Comparison of the performance of HPV tests in women with abnormal cytology: results of a study within the NHS cervical screening programme. Cytopathology. 2015;26(6):373-80. [DOI:10.1111/cyt.12210] [PMID]
31. Ovestad IT, Vennestrom U, Andersen L, Gudlaugsson E, Munk AC, Malpica A, et al. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol. 2011;123(2):278-83. [DOI:10.1016/j.ygyno.2011.07.024] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2021 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.